Harmony Biosciences is trading 4.01% up at $34.84 after the company announced it will report second quarter 2026 financial results on August 4, 2026.
- The announcement, made on July 21, 2026, provides investors with a near-term catalyst to trade ahead of the official earnings release.
- The stock is also benefiting from broader sector strength, with the biotech-focused XBI up 2.08% and U.S. equities trading higher overall.
- With no other major company-specific news reported, the move appears driven by earnings anticipation and positive momentum across the biotech tape.